Teva Q3 revenue falls 2% to $4.4 billion; GAAP EPS $0.20 vs. $0.37 a year earlier
Teva reported third-quarter 2026 revenue of $4.4 billion, down 2% from a year earlier, as lower U.S. sales of generic lenalidomide capsules offset growth in its key innovative brands. GAAP diluted EPS fell to $0.20 from $0.37, while non-GAAP diluted EPS rose to $0.86 from $0.78, and Teva raised 2026 revenue outlooks for AUSTEDO, AJOVY and UZEDY.
Key points
- Q3 2026 revenues were $4.4 billion, down 2% in both U.S. dollars and local currency, mainly due to lower lenalidomide capsule revenues in the U.S.
- GAAP diluted EPS was $0.20 versus $0.37 in Q3 2025; non-GAAP diluted EPS was $0.86 versus $0.78.
- Operating income was $714 million versus $882 million a year earlier, mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies.
- 2026 revenue outlooks raised for AUSTEDO to $2.55–$2.65 billion, AJOVY to $930–$960 million and UZEDY to $290–$310 million; total 2026 revenue outlook is $16.7–$17.0 billion.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.